Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 24 · below the Ichimoku cloud · RSI 32 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.7M | 0.00% | 346.93K | −45% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SGMT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Kemble GeorgeDirector | Conversion of Exercise of derivative security at price 6.36 per share. | 351K | $2.23M |
| Aug 13, 2026 | Kemble GeorgeDirector | Sale at price 10.23 per share. | 351K | $3.59M |
| Aug 10, 2026 | Kemble GeorgeDirector | Conversion of Exercise of derivative security at price 6.36 per share. | 20.2K | $128.51K |
| Aug 10, 2026 | Kemble GeorgeDirector | Sale at price 9.95 per share. | 20.2K | $201.15K |
| Jul 19, 2026 | Kemble GeorgeDirector | Sale at price 7.46 per share. | 18.8K | $140.53K |
| Jul 19, 2026 | Rozek ElizabethOfficer | Sale at price 7.76 per share. | 10.5K | $81.83K |
| Jul 19, 2026 | Happel DavidChief Executive Officer | Sale at price 7.76 per share. | 64.1K | $497.07K |
| Feb 18, 2026 | Martins Eduardo BrunoOfficer | Stock Award(Grant) at price 0.00 per share. | 44K | — |
| Feb 18, 2026 | Chauche ThierryChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 44K | — |
| Feb 18, 2026 | Rozek ElizabethOfficer | Stock Award(Grant) at price 0.00 per share. | 44K | — |
| Feb 18, 2026 | Happel DavidChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 128K | — |
| Feb 9, 2026 | Martins Eduardo BrunoOfficer | Sale at price 5.36 per share. | 3.6K | $19.51K |
| Feb 9, 2026 | Chauche ThierryChief Financial Officer | Sale at price 5.36 per share. | 1.3K | $7.03K |
| Feb 9, 2026 | Rozek ElizabethOfficer | Sale at price 5.36 per share. | 2.6K | $14.05K |
| Feb 9, 2026 | Happel DavidChief Executive Officer | Sale at price 5.36 per share. | 12.1K | $64.86K |
| Nov 19, 2025 | Kemble GeorgeOfficer and Director | Sale at price 7.69 per share. | 37.7K | $289.98K |
| Nov 3, 2025 | Rozek ElizabethOfficer | Stock Award(Grant) at price 0.00 per share. | 9.9K | — |
| Jul 20, 2025 | Martins Eduardo BrunoOfficer | Sale at price 9.13 per share. | 8.3K | $75.61K |
| Jul 20, 2025 | Rozek ElizabethGeneral Counsel | Sale at price 9.13 per share. | 10.8K | $98.47K |
| Jul 20, 2025 | Happel DavidChief Executive Officer | Sale at price 9.13 per share. | 65.5K | $598.12K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.2 | 0.7 | -8.5 | 53.7 | -9.2 | 6.0 | -8.0 | 44.3 | -3.7 | -23.6 | +27.4% | ||
| 2025 | -2.2 | -15.6 | -12.2 | 5.8 | 2.9 | 114.6 | 14.0 | -13.6 | -8.7 | 24.2 | -15.3 | -18.0 | +31.6% |
| 2024 | 74.9 | -35.3 | -11.6 | -28.0 | 36.7 | -35.8 | -1.8 | -8.3 | -10.1 | 85.9 | 10.5 | -20.9 | −17.0% |
| 2023 | -24.3 | -27.2 | -58.4 | 4.4 | 41.9 | −66.0% |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Buy / hold / sell counts